GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (FRA:LT4) » Definitions » ROE % Adjusted to Book Value

Liquidia (FRA:LT4) ROE % Adjusted to Book Value : -14.06% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Liquidia ROE % Adjusted to Book Value?

Liquidia's ROE % for the quarter that ended in Sep. 2024 was -105.74%. Liquidia's PB Ratio for the quarter that ended in Sep. 2024 was 7.52. Liquidia's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -14.06%.


Liquidia ROE % Adjusted to Book Value Historical Data

The historical data trend for Liquidia's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Liquidia ROE % Adjusted to Book Value Chart

Liquidia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - -67.06 -13.93 -11.92 -6.57

Liquidia Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.63 -13.38 -18.52 -9.99 -14.06

Competitive Comparison of Liquidia's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Liquidia's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Liquidia's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Liquidia's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Liquidia's ROE % Adjusted to Book Value falls into.



Liquidia ROE % Adjusted to Book Value Calculation

Liquidia's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-111.84% / 17.03
=-6.57%

Liquidia's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-105.74% / 7.52
=-14.06%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Liquidia ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Liquidia's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Liquidia Business Description

Industry
Traded in Other Exchanges
Address
419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Liquidia Headlines

No Headlines